This article is more than 5 years old. Information may no longer be current.

Pixium Vision releases 6-month update of Iris II epiretinal system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Pixium Vision’s epiretinal Iris II system for outer retinal degeneration improves visual performance after 6 months, but a shorter device lifespan has been detected, according to a press release.

Clinical safety and performance data at 6 months demonstrated the device had a favorable safety profile, the release said. However, new implantations have been temporarily halted while the company validates corrective measures with regulatory bodies regarding the lifespan of the Iris II system.

In this set of study patients, a shorter than expected lifespan of the device was noticed. The exchangeable design of the Iris II allows it to be replaced, and one replacement was completed successfully.

Iris II has a CE mark for outer retinal degeneration, including retinitis pigmentosa.